Recurrence of Bartholin gland mucinous adenocarcinoma managed with posterior exenteration: a case report

Blontzos, Nikolaos; Iavazzo, Christos; Giovannopoulou, Eirini; Novkovic, Natasa; Psomiadou, Victoria; Vorgias, George

doi:10.1080/01443615.2019.1650011

Cited by 1 publication

(4 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Details about number of patients, age, FIGO stage at presentation and histotype are reported in Table 1. 6 -41…”

Section: Resultsmentioning

confidence: 99%

“…Detailed data on patients’ recurrence site, secondary treatment and outcome are summarized in Table 2. 6 -41…”

Section: Resultsmentioning

confidence: 99%

“…Successful regional control of the recurrent disease with pelvic exenteration can increase long-term survival, despite the common perioperative complications. 76,77 Personalized therapeutic strategies for rare vulvar malignancy are needed. Genomic and molecular profiling of vulvar carcinoma highlighted that the most common types of mutation included PT53, CDKN2A (p16), and EGFR.…”

Section: Discussionmentioning

confidence: 99%

“…Successful regional control of the recurrent disease with pelvic exenteration can increase long-term survival, despite the common perioperative complications. 76,77…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Management of primary and recurrent Bartholin’s gland carcinoma: A systematic review on behalf of MITO Rare Cancer Group

Turetta,

Mazzeo,

Capalbo

et al. 2023

Tumori

View full text Add to dashboard Cite

Bartholin gland carcinoma is an extremely rare disease. Information regarding treatment is scarce and there is no strict consensus on best practice. All studies reporting cases of Bartholin’s gland cancer were screened and evaluated for inclusion. Baseline characteristics of studies were extracted. A total number of 290 manuscripts collected were available for the review process. Studies included in a previous systematic review were not duplicated. In total, details of 367 patients were collected, as follows: histological features, clinical presentation, treatment, recurrent rate, treatment of recurrence and outcome. About 35% of Bartholin gland carcinoma were squamous cell carcinoma. Almost 50% of patients presented with advanced stage. The therapeutic approach was mainly surgery, and in 61% of those women lymph node assessment was performed. Recurrence occurred in 21% of cases. Bartholin gland cancer remains a challenge for gynecologic oncologists. Guidelines, centralization to referral centers and standardized therapy are needed.

show abstract

“…Details about number of patients, age, FIGO stage at presentation and histotype are reported in Table 1. 6 -41…”

Section: Resultsmentioning

confidence: 99%

“…Detailed data on patients’ recurrence site, secondary treatment and outcome are summarized in Table 2. 6 -41…”

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

“…Successful regional control of the recurrent disease with pelvic exenteration can increase long-term survival, despite the common perioperative complications. 76,77…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations